Top Pharma Conferences 2023 | Pharmaceutical Sciences Meetings | Pharma Industry Conferences | USA | Europe | Asia | Middle East | Canada

Theme: Challenges and Advancements in Pharmaceutical Sciences

Pharma Europe 2023

Pharma Europe 2023

Welcome Message

Roy Krishna, Touro University, USA.

Dear Colleagues,

On behalf of Conference Series and the Organizing Committee it gives me immense pleasure to welcome you all to the Pharma Europe 2023 going to be held during March 13-14, 2023 in Frankfurt, Germany.

The past few years have been a global challenge as we navigate through the complexities of COVID-19 and its economic and health repercussions. We remember those who have lost loved ones in this pandemic and those who have borne the brunt of the symptoms. Comparatively speaking things are slowly easing but we know better to not let our guards down.

The pandemic has seen significant advances in pharmacological research resulting in COVID vaccinations and rapidly advancing therapeutic regimens.

This year’s Pharma Europe 2023 addresses various pharmacological sub disciplines including challenges in managing COVID-19. Your participation and contribution, allows us all to enhance our understanding of emerging therapeutics.

Attendees have multiple programs and tracks to benefit from and we also welcome our young researchers and contributors. No doubt this gathering is indeed a melting pot for global researchers, academicians and scientists.

Coming to venue; Frankfurt or Frankfurt am Main brings with the hustle and bustle of a cosmopolitan city. In this city tradition meets modernity. I certainly hope you all have a chance to see the sights of this global city.

We hope to have the opportunity to explore the sights, unparalleled history and cuisine of this cosmopolitan capital.

Roy Krishna, PhD, FCP.
Professor-Pharmacology,
College of Osteopathic Medicine,
Touro University, Nevada,
USA.

The most anticipated Pharma event in the world and you're invited to attend 33^rd Annual European Pharma Congress scheduled during March 13-14, 2023 at Frankfurt, Germany. which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions! This strategic conference will provide in-depth presentations and interactive sessions, for the possibility to network with like-minded professionals and discuss how to overcome the current challenges in pharmaceutical product synthesis and product development. The focus this year will be on the latest advancements, research and development to inspect the challenges in Pharmaceutical Sciences, Clinical Research and related areas. Pharma Europe 2023 is a specially designed cluster of all European Pharma conferences. The main theme of this Pharma conference is “Challenges and Advancements in Pharmaceutical Sciences ” which covers a wide range of critically important sessions.

At Pharma Europe 2023 meet your target audiences from around the world focused on learning about Pharma and Pharma regulations, licenses, approvals. This conference would be your single best opportunity to reach the largest assemblage of participants from the Pharma field.

2023 Highlights:

300+ Participation (70 Industry: 30 Academia)
10+ Keynote Speakers
50+ Plenary Speakers
20+ Exhibitors
14 Innovative Educational Sessions
5+ Workshops
B2B Meetings

Motives to attend:

This year, we will have more senior speakers, who will be joining us from pharmaceutical giants. They're coming to share their experience with us and ensure you can maximize your knowledge.
They also want to join us because they know how important it is to have your questions answered. In light of all that's happening in the Pharmaceutical industry, this year delivers more case studies for you to gain first-hand experience on developing your drugs, clinical trials, and we will be introducing think tank sessions to discuss and debate challenges in more detail with key decision makers. These sessions will bring you constructive networking possibilities so you return to work with practical solutions for your challenges.
Get ahead of the competition: Gather fresh intuitions from key speakers to help make restored decisions on doing business in Pharma
Meet & Connect with Senior Stakeholders from the global Pharma network
Content your way: Access a variety of technical and commercial tracks across the entire supply chain, or choose the one track that is most relevant to your business
Save months of research: Don’t spend eras reading whitepapers, come and hear from the decision makers themselves on the latest trends, challenges and opportunities at the forefront of the industry
A Unique Opportunity for Advertisers and Sponsors at this International event
Triumph of Awards, Certificates recognizes your commitment to your profession to encourage the nascent research.

Over 50+ organizations and international pavilions will be exhibiting at the Pharma Europe 2023 conference. Exhibitors will include equipment manufacturers and suppliers, systems providers, finance and investment firms, R&D companies, project developers, trade associations, and government agencies.

In addition to the products and services you will have access to valuable content, including Keynote Presentations, Product Demonstrations and Educational Sessions from today’s industry leaders.

Target Audience:

Directors, CEO’s of Organizations
Business Development Managers
Chief Scientific Officers
R&D Researchers from Pharma Industries
Professors, Associate Professors, Assistant Professors
PhD Scholars
Patent Attorneys
Investment Analysts
Association, Association presidents and professionals
Noble laureates in Health Care and Medicine
Bio instruments Professionals
Bio-informatics Professionals
Software development companies
Research Institutes and members
Supply Chain companies
Manufacturing Companies
CRO and DATA management Companies
Training Institutes
Business Entrepreneurs

Track 1: Pharmaceutical Sciences

The Pharmaceutical sciences combine broad range of scientific disciplines that are critical to the discovery and development of new drugs and therapies. Pharmaceutical Sciences is a dynamic and interdisciplinary field that aims to integrate fundamental principles of physical and organic chemistry, engineering, biochemistry, and biology to understand how to optimize delivery of drugs to the body and translate this integrated understanding into new and improved therapies against human disease. At the many of institutes internationally recognized faculty contribute to the field through inquiry into the underlying mechanisms of drug interactions with the human body and development of advanced synthetic or biologically-derived materials that can modulate these interactions in pursuit of better and safer therapies and drug products. The worldwide market for pharmaceutical science instruments and reagents came to $47.8 billion in 2012. This figure is relied upon to increment to $51.3 billion in 2013 and $77.6 billion in 2018, with an anticipated five-year compound yearly development rate (CAGR) of 8.6%.

Related Societies:

Societies in USA: American Society of Pharmacognosy (ASP), Phytochemical Society of North America (PSNA), The Herb Society of America, American Herbal Products Association (AHPA)

Societies in Europe: Phytochemical Society of Europe (PSE), Society for Medicinal Plant and Natural Product Research, European Herbal and Traditional Medicines Association (EHTPA)

Societies in Asia and Pacific: The Asian Society of Pharmacognosy (ASP), Society of Pharmacognosy, Malaysian Natural Product Society (MNPS), The Japanese Society of Pharmacognosy, Australian Society of Plant Scientists

Track 2: Pharmaceutical Chemistry

Pharmaceutical chemistry is the study of drugs, and it involves drug development. This includes drug discovery, delivery, absorption, metabolism, and more. There are elements of biomedical analysis, pharmacology, pharmacokinetics, and pharmacodynamics. Pharmaceutical chemistry work is usually done in a lab setting. The chemical industry is one of the world’s largest branches and has significant influence on many other industries. Total global chemical shipments are worth an enormous five billion U.S. dollars.

Related Societies:

Societies in USA: American College of Clinical Pharmacology, American Society for Clinical Pharmacology and Therapeutics, American Neurological Association (ANA), American Society of Neuroimaging, American Board of Psychiatry and Neurology (ABPN), American Academy of Neurology (AAN)Societies in Europe: The Federation of European Pharmacological Societies, The European Association for Clinical Pharmacology and Therapeutics (EACPT), The European Behavioural Pharmacology Society (EBPS), British Pharmacological Society

Societies in Asia and Pacific: Korean Society of Pharmacology, Malaysian Society of Pharmacology and Physiology (MSPP), Pharmacological Society of Taiwan, Japanese Pharmacological Society

Track 3: Drug Regulations

Drugs and Regulations are very important in aspects of Pharmaceutical sciences where it deals with Drug safety, Cost effectiveness, Drug rediscovery, Pharmaceutical services, Role of pharmacists, Radio Pharmaceuticals and Multiple drug use etc. The regulation of drugs varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level or at both state and national levels by various bodies, as is the case in Australia.

Related Societies:

Societies in USA: Accreditation Council for Pharmacy Education, American Institute of the History of Pharmacy, American Society of Health-System Pharmacists, American Society of Consultant Pharmacists(ASCP)

Societies in Europe: European Medicines Agency, Federal Agency for Medicines and Health Products (FAGG), Danish Health and Medicines Authority (SST), Bulgarian Drug Agency (BDA), Federal Institute for Drugs and Medical Devices (BfArM), National Organization for Medicines (EOF)

Societies in Asia and Pacific: China Food and Drug Administration (CFDA), Drug Office - Department of Health, Pharmaceuticals and Medical Devices Agency (PMDA), Ministry of Food and Drug Safety (MFDS), Pharmacy and Drug Control

Track 4: Pharmaceutical Formulations

Pharmaceutical formulations, in pharmaceutics, are the process in which different chemical substances, including the active drug, are combined to produce a final medicinal product. The word formulation is often used in a way that includes dosage form. Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally taken drugs, this usually involves incorporating the drug into a tablet or a capsule.

Related Societies:

Societies in USA: American Coatings Association, Parenteral Drug Association (PDA), American Association of Pharmaceutical Scientists (AAPS), Consumer Healthcare Products Association, American Urological Association (AUA), Pharmacy Society of Wisconsin (PSW),

Societies in Europe: Pharmaceutical Society of New Zealand Incorporated (PSNZI), Royal Pharmaceutical Society (RPS), Association of British Pharmaceutical Industry (ABPI)

Societies in Asia and Pacific: Bangladesh Pharmaceutical Society (BPS), Society for Pharmaceutical Dissolution Science (SPDC), Pharmaceutical and Bioscience Society (PBS)

Track 5: Pharmaceutical Nanotechnology

Sometimes called, molecular manufacturing is a branch of engineering that deals with the design and manufacture of extremely small electronic circuits and mechanical devices built at the molecular level of matter. Nanotechnology is also being applied to or developed for application to a variety of industrial and purification processes. Purification and environmental clean-up applications include the desalination of water, water filtration, wastewater treatment, groundwater treatment, and other Nano remediation.

The global market for nanotechnology dots was estimated to generate $121.0 million in revenues in 2013. This market is expected to reach about $1.1 billion in 2016 and about $3.1 billion by 2018, at a compound annual growth rate (CAGR) of 90.8% for the five-year period, 2013 to 2018.

Related Societies:

Societies in USA: American Nano Society: Nanotechnology Community, American Academy of Nano Medicine, International Association of Nanotechnology, Microscopy Society of America, American Bar Association Section Nanotechnology Project, American Chemical Society - Nanotechnology Safety Resources.

Societies in Europe: European Nanoscience and Nanotechnology Association, European Nano Technology Gateway, British Society for Nano Medicine, Scottish Center for Nano Technology in Construction Materials, British Society for Nanomedicine.

Societies in Asia and Pacific: Asia Nano Forum, Asian Nanoscience And Nanotechnology Association

Track 6: Drug Delivery Systems

The method by which a drug is delivered can have a significant effect on its efficacy. Some drugs have an optimum concentration range within which maximum benefit is derived, and concentrations above or below this range can be toxic or produce no therapeutic benefit at all. On the other hand, the very slow progress in the efficacy of the treatment of severe diseases, has suggested a growing need for a multidisciplinary approach to the delivery of therapeutics to targets in tissues.

Related Societies:

Societies in USA: Controlled Release Society, Society for Biomaterials, American Chemical Society, American Coatings Association, Parenteral Drug Association, American Association of Pharmaceutical Scientists (AAPS)

Societies in Europe: The British Society for Nanomedicine, European Society for Biomaterials, Royal Pharmaceutical Society of Great Britain, Turkish Pharmacists Association

Societies in Asia and Pacific: Pharmaceutical Society of Korea, Pharmaceutical Society of Australia, Pharmacy Guild of Australia

Track 7: Pharmaceutics

Pharmaceutics plays an important role in drug discovery like drug disposition, Innovations in clinical development, Pharmaceutical technology, Pharmaceutics and drug delivery, Drug design, Targeted drug, gene delivery, Sustained drug delivery system, Routes of administration, Fundamental drug development.

The global market for quantum dots (QDs) was estimated to generate $121 million in revenues in 2013. This market is expected to reach about $1.1 billion in 2016 and about $3.1 billion by 2018, at a compound annual growth rate (CAGR) of 90.8% for the five-year period, 2013 to 2018.

Related Societies:

Societies in USA: American Statistical Association, Controlled Release Society, Society for Biomaterials, American Chemical Society, American Coatings Association, Parenteral Drug Association, American Association of Pharmaceutical Scientists (AAPS), Parenteral Drug Association (PDA), The International Society of Biopharmaceutical Statistics.

Societies in Europe: European Biopharmaceutical Enterprises, The Danish Society for Biopharmaceutical Statistics, European Society for Biomaterials, Royal Pharmaceutical Society of Great Britain, Turkish Pharmacists Association

Societies in Asia and Pacific: Chinese Biopharmaceutical Association, Pharmaceutical Society of Australia, Pharmacy Guild of Australia, Chinese American Biopharmaceutical Society.

Track 8: Pharmaceutical Engineering

Pharmaceutical engineering is a branch of engineering focused on discovering, formulating, and manufacturing medication, as well as analytical and quality control processes. It utilizes the fields of chemical engineering, biomedical engineering, and Pharmaceutical sciences.

The global genetic engineering market is expected to reach $3,514.08 Million by 2019 from $1,845.25 Million in 2014, growing at a CAGR of 13.75%. Increased RandD expenditure and growth of biotechnology and pharmaceutical industries, increased funding for genomics research, and technological advancements are the primary growth drivers for this market during the forecast period (2014–2019).

Related Societies:

Societies in USA: American Society of Gene Therapy, Biotechnology and Biological Research Council, Genetics Society of America, The American Society of Human Genetics, Center for Genetics and Society, National Society of Genetic Counselors, American Society for Cell Biology.

Societies in Europe: European Society of Human Genetics, European Peptide Society, European Federation of Biotechnology, European Association of Pharma Biotechnology, German Resource Centre for Genome Research, European federation of biotechnology https://europe.pharmaceuticalconferences.com/registration.php

Societies in Asia and Pacific: Asia Pacific Society of Human Genetics, Asia-Pacific Society of Eye Genetics, Asia Pacific Society of Human Genetics, Genetics Society of Thailand.

Track 9: Pharmaceutical Microbiology

Pharmaceutical Microbiology is involves in the study of microorganisms associated with the manufacture of pharmaceuticals e.g. minimizing the number of microorganisms and is a specialist area of microbiology and one concerned with the use of microorganisms in pharmaceutical development and with maintaining contamination control.

Related Societies:

Societies in USA: US Radiopharmaceuticals, NCM USA, Avid Radiopharmaceuticals, Inc, Society of Nuclear Medicine and Molecular Imaging (SNMMI), American College of Nuclear Medicine (ACNM), American Society of Nuclear Cardiology

Societies in Europe: European Association of Nuclear Medicine, Society of Radiopharmaceutical Sciences, British Nuclear Medicine Society, Society of Nuclear Medicine.

Societies in Asia and Pacific: Asia Pacific Society for Materials Research, Nuclear Medicine Society(Singapore), Society of Nuclear Medicine India, Asia and Oceania Federation of Nuclear Medicine and Biology(AOFNMB).

Track 10: Pharma Companies

Pharma Companies in Europe - Kowa Pharmaceutical, Aegerion Pharmaceuticals Ltd, Kent Pharmaceuticals, Alan Pharmaceuticals, Alliance Pharmaceutical Limited. Pharmaceutical Companies are knowledge driven industry and is heavily dependent on Research and Development for new products and growth. However, basic research discovering of new molecules is a time consuming and expensive process and is thus, dominated by large global multinationals.

Related Societies:

Societies in Asia and Pacific: Chinese Biopharmaceutical Association, Pharmaceutical Society of Australia, Pharmacy Guild of Australia, Chinese American Biopharmaceutical Society

Track 11: Clinical Pharmacy

Clinical pharmacy is the branch of pharmacy in which clinical pharmacists provide direct patient care that optimizes the use of medication and promotes health, wellness, and disease prevention.

Clinical Pharmacy is a unique service provided by the leading pharmacy departments in the United States. The concept of Clinical Pharmacy evolved after the significant increase in number of pharmaceuticals in the market and the increasing potential of drug interactions.

Related Societies:

Societies in USA: American Society of Health-System Pharmacists, American Pharmacists Association, South Carolina Society of Health-System Pharmacists, Oregon Society of Health Systems Pharmacists, Massachusetts Society of Health-System Pharmacists, Canadian Pharmacists Association

Societies in Europe: The Federation of European Pharmacological Societies, European Association of Employed Community Pharmacists in Europe (EPhEU), European Pharmaceutical Union (EPU), Pharmaceutical Group of the European Union (PGEU), Danish Association of Pharma Economists.

Societies in Asia and Pacific: Chinese Pharmaceutical Association, Indian Pharmacist Association, Kuwait Pharmaceutical Association, Pharmaceutical Association of Mauritius.

Track 12: Industrial Pharmacy

Industrial Pharmacy also plays a crucial role in any drug discovery. To any novel drug discovery the industrial approach is very important to get massive commercial application. Few things which have to be considered by industries to provide a safe and cost affective medicine to the patients like Supply chain, Waste management, Product management, Post- marketing surveillance, Good manufacturing practices and Marketing.

The U.S. pharmaceutical market is the world’s most important national market. Together with Canada and Mexico, it represents the largest continental pharma market worldwide. The United States alone holds some 40 percent of the global pharmaceutical market. In 2014, this share was valued around 365 million U.S. dollars. Many of the global top companies are located in the United States. In 2014, six out of the top eleven companies were U.S.-based.

Related Societies:

Societies in USA: Industry Pharmacists Organization, American Pharmacists Association, American Association of Pharmaceutical Scientists (AAPS), American Statistical Association, Controlled Release Society, Society for Biomaterials, American Chemical Society, American Coatings Association, Parenteral Drug Association, American Association of Pharmaceutical Scientists (AAPS), Parenteral Drug Association (PDA), The International Society of Biopharmaceutical Statistics.

Societies in Asia and Pacific: Chinese Biopharmaceutical Association, Pharmaceutical Society of Australia, Pharmacy Guild of Australia, Chinese American Biopharmaceutical Society.

Track 13: Pharmaceutical Biotechnology

Pharmaceutical biotechnology is a relatively new and growing field in which the principles of biotechnology are applied to the development of drugs. A majority of therapeutic drugs in the current market are bioformulations, such as antibodies, nucleic acid products and vaccines.

Related Societies:

Societies in USA: National Association of Pharmacy Regulatory Authorities, Regulatory Affairs Professionals Society (RAPS), Regulatory Affairs - American Chemical Society, The Organisation for Professionals in Regulatory Affairs; Regulatory Affairs North America, Society of Quality Assurance

Societies in Europe: European Society of Regulatory Affairs, Legal and Regulatory Affairs Committee

Societies in Asia and Pacific: Regulatory Affairs Professionals Society Singapore, Pharmaceutical Society of Australia, Pharmacy Guild of Australia, Chinese American Biopharmaceutical Society.

Track 14: Pharmacy Development Services

Pharmacy Development Services offers independent pharmacy owners profit-generating strategies in operations, business development, data analytics, and many more .The Pharma consultants work with organizations of all sizes including academic institutes, start-up companies, and established organizations. The services aims to increase the patient’s knowledge of their medication and improve their adherence to the regimen. Globally Pharma Market ranges from $870-$900 billion and in Europe $260-$280 billion from which Germany provides ready access to internationally renowned scientists, world-class research and pharmaceuticals markets.

Globally Pharma Market ranges from $870-$900 billion and in Europe $260-$280 billion from which Germany provides ready access to internationally renowned scientists, world-class research and pharmaceuticals markets.

Related Societies:

Societies in Asia and Pacific: Chinese Biopharmaceutical Association, Pharmaceutical Society of Australia, Pharmacy Guild of Australia, Chinese American Biopharmaceutical Society.

Track 15: Pharmacognosy

Pharmacognosy is the study of drugs derived from Plants and herbs. The Drugs from natural sources can be obtained by the help of following methods like Computational chemistry, Medicinal chemistry, Molecular drug design, Protein structure prediction, molecular simulation, and exploratory development and Biochemistry. Global sales of plant products was totally estimated us $60 billion in 2002 and is expected to get higher at 6.4 % average growth rate.

Related Societies:

Societies in Asia and Pacific: Chinese Biopharmaceutical Association, Pharmaceutical Society of Australia, Pharmacy Guild of Australia, Chinese American Biopharmaceutical Society.

Track 16: Pharmacological Sciences

Pharmacology is the study of the biochemical and physiological effects of active ingredient on humans. The various aspects of pharmacological sciences are Behaviouralpharmacology, Medical Pharmacology, Cardiovascular pharmacology, Endocrine pharmacology, Clinical pharmacology, Urogenital pharmacology, Pharmacokinetics, Neuropharmacology, Immune pharmacology, Cognitive models of the brain, Neural models of memory, Functional modes of the brain, Neuropsychology, Cognitive neuroscience and neurosystems.

The drug market was valued at nearly $5.8 billion during 2011 and will reach nearly $5.7 billion during 2012. Total value is expected to reach nearly $6 billion in 2018

Related Societies:

Societies in Asia and Pacific: Chinese Biopharmaceutical Association, Pharmaceutical Society of Australia, Pharmacy Guild of Australia, Chinese American Biopharmaceutical Society.

Track 17: Bioinformatics

Bioinformatics has emerged out of the inputs of specialists from several different areas such as biology, biochemistry, biophysics, molecular biology, and biostatistics and computer science. Specially designed algorithms and organised computer databases are at the core of all bioinformatic operations. Algorithms, that are necessarily complex, make voluminous data easy to handle for defined purposes, in an amazingly short time, a process that is humanly impossible.

The global market for Bioinformatics is expected to grow from nearly $2.3 billion in 2014 to nearly $3.4 billion in 2019, with a compound annual growth rate (CAGR) of 8.3% for the period of 2014-2019.

Related Societies:

Societies in Asia and Pacific: Chinese Biopharmaceutical Association, Pharmaceutical Society of Australia, Pharmacy Guild of Australia, Chinese American Biopharmaceutical Society.

The Growing Pharmaceuticals Market: Expert Forecasts and Analysis

The global pharmaceuticals market was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%, according to a recent pharma market research report by The Business Research Company.

This is an accelerated pace compared to 5.2% for the years before 2017, but is slower than the other two large healthcare segments, medical equipment and healthcare services. Healthcare as a whole is growing at over 7% year on year.

The factors that affect the pharmaceutical market size include disease prevalence, drug affordability, consumer attitudes, government policies and some supply-side factors:

Disease prevalence is related to population size, age, genetic inheritance and behaviour (infectious disease incidence is lower where sanitation practices are better; sedentary lifestyles also encourage chronic disease).
Affordability is related to income but also to drug prices.
Consumer attitudes include willingness to use alternative therapies or distrust of taking drugs.
Government (and insurance company) policies affect reimbursement and who the payer is. Other government policies determine regulation, which can be a significant barrier to the launch of new treatments.
A major supply-side factor is availability of an appropriate treatment, which may be a matter of quantity, as in an epidemic, or of drug discovery and development.

PESTEL Analysis for the Pharmaceuticals Market

Current and ongoing changes in political, economic, social, technological, legal and environmental factors are influencing growth in the healthcare market, where drugs play an important part. The following factors are all boosting healthcare market growth:

Reduced taxes and lowered drug prices in the USA
GDP growth of over 6% in China and India
Widespread population aging and sedentary lifestyles leading to increased chronic disease prevalence
Industrialized data services in R&D enabling the use of clinical trial data in trial simulations
Lowered regulatory barriers for new drugs in the USA
High urban pollution levels increasing the incidence of conditions like asthma

As a result, healthcare expenditure per capita is set to rise from its 2017 level of $1137 to $1427 by 2021.

Pharmaceutical Market Restraints and Drivers

Part of the explanation for the relatively slow current growth of the pharma market is that the launch of major new products has slowed and that companies are restricting their R&D investment. For example, despite the huge potential for any effective and safe new drug for treating Alzheimer’s disease, Pfizer has ended its Alzheimer’s research program while AstraZeneca and GSK have cut back. High failure rates, the $2 billion average cost of developing a new drug, and falling returns on investment — down from 10.1% a year in 2010 to 3.2% in 2017 for the big pharma companies, according to Deloitte’s — are restraining the launch of high-priced new breakthrough drugs such as those that boosted the market in earlier years.

Most pharmaceutical industry growth now is coming instead from the increased size of the global aging population, which boosts demand for long-term treatments for chronic diseases, and better access to healthcare in emerging economies.

The Changing Geography of Pharma Markets

Growth over past decades means that North America and Western Europe still account for 56% of the global market, but Asia Pacific has overtaken Western Europe as the second largest region. Growth in Asia Pacific is fueled by increased affordability of drugs resulting from the launch of low-priced generics. Other factors that are positive for growth in Asia Pacific are the rise of GDP per capita in the region, government programs to support healthcare, and rapid urbanization, which brings both doctors and pharmacies within easy reach of increasing proportions of growing populations. Pharma sales in Asia Pacific will grow at 8.4% a year to 2021.

The story is a similar one at the level of country. The USA, by itself worth 25% of the global total, is restraining global growth by rising at below 5% a year, while the much smaller pharma markets of India and China are both achieving double that pace.

Key Segments in the Pharmaceutical Market

The largest pharma market globally is for musculoskeletal drugs. These are treatments for diseases such as rheumatoid- and osteo- arthritis, osteoporosis, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus and others. Major drugs in this segment include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The segment accounted for 14% of the global total in 2017. Cardiovascular, oncology and ant-infective drugs are the second third and fourth largest markets.

Drugs for treating metabolic disorders such as diabetes and diseases of the thyroid and pituitary glands will be the fastest-growing segment of the global pharma market to 2021. This segment will grow at 9% a year going forward, following recent growth of 11.6%, but it will remain in fifth place for market size.

Anti-diabetic drugs are the largest subsegment of the global pharmaceutical industry, worth over $85 billion in 2017; second are the anti-virals and third come anti-hypertensives. Drugs for some of the less prevalent cancers — thyroid, skin and ovarian cancer — are the fastest-growing subsegments. This is in part because the US Federal Drug Administration has allowed a less rigorous regulatory procedure and lower endpoint benchmark for cancer drugs, so increasing the rate of innovation.

Competitive Landscape & Top Pharmaceutical Companies

Pharmaceutical drugs are subject to a large number of laws and regulations that deal with patenting, testing, safety, efficacy and marketing and affect the size and growth rates of the market. Together with the high R&D costs involved in creating new drug solutions, these can act as barriers to entry for small companies. However, pharmaceutical companies produce both generic and branded drugs. Generics, which are copies of patent-expired drugs, are opportunities for smaller entrants. They are taking an increasing share of the market, particularly in developing economies, where governments are encouraging their production in order to make lower-price treatments more widely available.

In the overall market, top pharmaceutical companies include:

Novartis
Sanofi
Pfizer
Hoffman-La Roche
Gilead

Together the top ten pharmaceutical companies account for 30% of global sales, making the market moderately fragmented. Within individual segments, however, the share of these pharmaceutical companies varies: Hoffman-La Roche is by some way the leading pharmaceutical company in the large oncology drugs market, but Sanofi leads in the cardiovascular and metabolic disorders segments.

In markets where biologics have penetrated, the leading players are not in the top ten pharma manufacturers: Biogen, for instance, leads in the central nervous system segment, while Bristol-Myers Squibb and Eli Lilley have significant shares in oncology.

Deal activity in the healthcare industry has surged in recent years. Most mergers and acquisitions are aimed at boosting product portfolios and expanding the market reach of products and services. For example, in August 2014 Merck acquired a clinical-stage pharmaceutical company, Idenix Pharmaceuticals Inc., for nearly $4 billion. Through this acquisition Merck strengthened its product portfolio by adding Idenix’s potential hepatitis drugs.

Data Segmentations: Pharmaceutical drugs global market, global pharmaceutical drugs market by therapeutic area segments and subsegments; pharmaceutical drugs market by region and country and by therapeutic area segments; branded versus generic drugs markets by country; competitor drug sales and market shares by therapeutic area; global healthcare market historic and forecast size and growth; healthcare market regional and country size and growth; healthcare market competitive landscape.

A look ahead into 2019 Global Market Analysis :

One of the key items to look for in 2019 is how the pharmaceutical industry will fare with new product approvals. In 2018, the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved a record-high 59 new molecular entities (NMEs), surpassing the previous record of 53 NME approvals in 1996 and the 46 NMEs approved in 2017. The 59 NME approvals in 2018 was nearly double the 10-year (2009–2017) average of 33 NME approvals by FDA’s CDER. The record-number of NME approvals continues an upward trajectory for NME approvals (with the exception of 2016 when 22 NMEs were approved) over the last several years. FDA’s CDER approved 41 NMEs in 2014, 45 NMEs in 2015, 46 NMEs in 2017, and the 59 NMEs thus far in 2018.

In addition, continuing a recent trend, orphan drugs accounted for a large percentage of NME approvals. More than half (58%), or 34, of the NME approvals in 2018 were for orphan drugs, defined as drugs that treat 200,000 or fewer people in the US. In 2017, 39%, or 18 of the 46 NMEs approved by the FDA’s CDER were orphan drugs, which continued a recent trend of approximately 40% of NME approvals being orphan drugs. In 2016, 9 of the 22 NMEs approved by the FDA were orphan drugs. Of these 22 NME approvals, two were diagnostic agents, so 9, or 45%, of the new drugs approved in 2016 were orphan drugs. In 2015, 47%, or 21 of the 45 NMEs approved by the FDA’s CDER were orphan drugs, and in 2014, 41%, or 17 of the 41 NMEs approved were orphan drugs.

The key question for the pharmaceutical industry in 2019 is whether the innovation train will continue to roll.

Despite the optimism for product innovation based on NME approvals in 2018, other issues may have a dampening effect, notably financing into the biopharmaceutical industry. “Biopharma has had a rocky few months, and many expect life to get tougher as we head into 2019,” said Amy Brown, author of a recent report by Vantage, the editorial arm of Evaluate Ltd, in highlighting key predictions for the pharmaceutical industry in 2019. “The sector will need to deliver on its innovation promises next year if it wants to rise above wider economic and financial concerns.”

In the US, a total of $4.0 billion was invested into biotechnology-related industries in the third quarter of 2018 (the latest available data as of press time), which represented a 1% decrease from the second quarter of 2018 while deals remained constant quarter on quarter with 120 deals each in the third and second quarters of 2018, according to the Healthcare MoneyTree report by PwC and CB Insights. The biotechnology subsector raised $2.160 billion in the third quarter of 2018, a 7% increase from the second quarter of 2018. Out of the 59 deals, closed in the third quarter, six were mega-round deals, which contributed $1.176 billion of the dollars invested in the third quarter. The drug-development subsector raised $884 million in the third quarter of 2018, a 31% decrease from the second-quarter of 2018. Out of the 31 deals closed, none were mega-round deals. For the other subsectors in biotechnology-related industries, the medial device & equipment industry raised $750 million in 45 deals in the third quarter of 2018, a decrease of 4% from the second quarter of 2018, in terms of dollars invested, according to the PwC/CB Insights’ Healthcare MoneyTree report. The drug-discovery subsector raised $517 million in 16 deals in the third quarter of 2018, and the disease-diagnosis subsector raised $325 million in five deals.

The Vantage report also made several other noteworthy predictions relating to product developments for 2019. AbbVie’s Humira (adalimumab), an anti-inflammatory drug for treating arthritis, plaque psoriasis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis, will continue to be the world’s biggest-selling drug in 2019, with sales of just under $21 billion. For new product launches in 2019, Alexion Pharmaceuticals’ Ultomiris (ravulizumab) for treating adult patients with paroxysmal nocturnal hemoglobinuria, a rare and life-threatening blood disease, which was approved by the FDA in December 2018, has potentially the largest upside for a new drug approval with a net present value of $10.9 billion. The Vantage report also predicts that AstraZeneca will net the most new sales in 2019, increasing by $2.3 billion over the previous year’s total.

Macroeconomic changes will also be an important consideration for 2019. A recent analysis by PwC for its 2019 global outlook noted a slowdown in global economic growth following a mini-boom between the end of 2016 and early 2018. In the US, the PwC report projects that the boost from fiscal stimulus is likely to fade, higher interest rates may dampen consumer spending and a strong dollar could continue to drag on net exports for growth to moderate from an estimated 2.8% in 2018 to around 2.3% in 2019. On the plus side, the US will record its longest-ever business cycle expansion in July 2019, when the period of growth that began in mid-2009 surpasses the length of the expansion that ran from 1991 until 2001, but this could come to an end in 2020 or 2021, according to the PwC analysis.

In the Eurozone, the PwC report projects that uncertainty relating to global trade tensions and Brexit will take a toll while the European Central Bank is likely to offer less support to growth as its quantitative easing policy ends. Growth in China is also expected to slow relative to 2018 due to potential impact of US tariffs and the need for the government to control debt. The report also noted that other emerging market currencies could come under periodic pressure from a strong US dollar, but this effect is likely to lessen later in 2019 due to the US economy slowing.

The PwC report also says that trade wars will continue in 2019, which will impact overall economic performance but also create uncertainty for policy makers in terms of considering the impact of potential tariffs on growth and inflation and for businesses, which will seek to mitigate the impact on their supply chains and customers. The main focus of tensions is likely to remain US-China trade although the report points out other scenarios are possible.

Conference series hosted 32^nd Annual European Pharma Congress 2022 April 25-26, 2022 at Barcelona, Spain

Active participation and generous response were received from the Organizing Committee Members, scientists, researchers, as well as experts from Non-government organizations, and students from diverse groups who made this conference as one of the most successful and productive events in 2022 from Conference series.

The conference was marked with several workshops, multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from scientists, young and brilliant researchers, business delegates and talented student communities representing more than 35 countries, who have driven this event into the path of success.

The conference was initiated with a warm welcome note by Honourable guests and the Keynote forum. The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following Speakers were highlighted as

Keynote speakers:

Dr Thomas McCune – MD, Division of Nephrology, EVMS,USA.

A.C MATIN – Professor of Microbiology and Immunology, Standford Univery, USA

We are obliged to the various delegates from companies and institutes who actively took part in the discussions. We sincerely thank the Organizing Committee Members and Editorial board of Pharma Europe 2022 for their gracious presence and continuous support throughout the proceedings of this event. With the valuable feedback and generous response received from the participants of the event, Conference Series would like to announce the commencement of “33^rd Annual European Pharma Congress 2023”

For details Visit: https://europe.pharmaceuticalconferences.com/

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	March 13-14, 2023
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1
Poster Opportunity Closed	Click Here to View